Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 694-898-7 | CAS number: 23121-00-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Skin sensitisation
Administrative data
- Endpoint:
- skin sensitisation: in vivo (LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 07 - 23 Sep 2016
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 016
- Report date:
- 2016
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)
- Version / remarks:
- adopted in 2010
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.42 (Skin Sensitisation: Local Lymph Node Assay)
- Version / remarks:
- updated 06 July 2012
- Deviations:
- not specified
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- Hess. Ministerium für Umwelt, Energie, Landwirtschaft und Verbraucherschutz, Wiesbaden, Germany
- Type of study:
- mouse local lymph node assay (LLNA)
Test material
- Reference substance name:
- 4-(2-phenylpropan-2-yl)phenyl 4-oxo-3-(λ⁵-diazynylidene)-3,4-dihydronaphthalene-1-sulfonate
- Cas Number:
- 23121-00-8
- Molecular formula:
- C25H20N2O4S
- IUPAC Name:
- 4-(2-phenylpropan-2-yl)phenyl 4-oxo-3-(λ⁵-diazynylidene)-3,4-dihydronaphthalene-1-sulfonate
- Test material form:
- solid
Constituent 1
- Specific details on test material used for the study:
- STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: room temperature, protected from light
In vivo test system
Test animals
- Species:
- mouse
- Strain:
- CBA/Ca
- Remarks:
- Ola Hsd
- Sex:
- female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: Envigo RMS B.V., Inc, Horst, The Netherlands
- Females nulliparous and non-pregnant: yes
- Age at study initiation: 10 - 12 weeks (pre-test), 11 - 12 weeks (main study)
- Weight at study initiation: 20.6 - 23.7 g (pre-screen test) (range), 18.1 - 24.3 g (main study) (range)
- Housing: 2 - 4 animals per cage, in Makrolon Type II (pre-screen test) / III (main study), with wire mesh top and granulated soft wood bedding
- Diet: 2018C Teklad Global 18% protein rodent diet, ad libitum
- Water: tap water, ad libitum
- Acclimation period: at least 5 days
- Indication of any skin lesions: no
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 2
- Humidity (%): 45 – 65
- Photoperiod (hrs dark / hrs light): 12 / 12
Study design: in vivo (LLNA)
- Vehicle:
- dimethylformamide
- Remarks:
- (DMF)
- Concentration:
- 10, 25 and 50%
- No. of animals per dose:
- 1 female (pre-screen test)
4 females (main test) - Details on study design:
- PRE-SCREEN TESTS:
Two concentrations (25 and 50% dissolved in DMF) were applied topically to the ears of each animal (one mouse per concentration), once a day for 3 consecutive days. Animals were observed for clinical signs of systemic toxicity and local irritation at the application site at least once daily. Furthermore, body weights and ear thickness measurements were performed (body weight: before initial application and on Day 6, ear thickness: before initial application, on Day 6 and on Day 3). None of the animals showed any signs of systemic toxicity. The ears were punched after sacrifice (Day 6) at the apical area using a biopsy punch (Ø 8 mm, corresponding to 0.5 cm²), pooled per animal and weighed using an analytical balance. The animal treated with 50% test item showed a very slight erythema of the ear skin (score 1), while the animal treated with 25% did not show any signs of signifcant irritation (indicated by an erythema score ≥ 3 and /or an increase of less than 25% in ear thickness). No mortality was observed.
Based on these results and considering that 50% was the maximum attainable concentration, 50% (w/v) was selected as the highest test concentration for the main study. This concentration was expected not to induce systemic toxicity, nor to induce an increase in ear thickness exceeding 25% or to induce dermal erythema with a score of 3 or more.
- Compound solubility: 50% (maximum attainable concentration)
- Irritation: slight irritation (score 1) was observed in 1/2 animals
- Systemic toxicity: no systemic toxicity was observed
- Ear thickness measurements: yes (less than 25% increase in ear thickness was measured)
- Erythema scores: 1 (test animal treated with 50% of test item, 24 h after second application, fully reversible within 6 days)
MAIN STUDY
ANIMAL ASSIGNMENT AND TREATMENT
- Name of test method: 3H-methyl thymidine (3HTdR) incorporation, determined by ß-scintillation
- Criteria used to consider a positive response: SI ≥ 3
TREATMENT PREPARATION AND ADMINISTRATION:
25 μl of each dose formulation (10, 25 and 50%) or the vehicle alone were applied to the dorsal skin of each ear of each animal once a day for 3 consecutive days. On Day 6, 19.8 μCi 3H-methyl thymidine, contained in 250 μL of PBS (= 79.1 μCi/mL), was administered to each mouse via the tail vein. Approximately 5 h after administration, local lymph nodes were collected, pooled and separated by gentle mechanical disaggregation through a stainless steel gauze (200 μm mesh size). After washing two times in PBS the lymph node cells were treated with ~3 mL of 5% trichloroacetic acid (TCA) at ~4 °C for at least 18 h before the determination of the amount of 3H-methyl thymidine incorporation (as disintegrations per minutes (DPM)) on Day 7. - Positive control substance(s):
- hexyl cinnamic aldehyde (CAS No 101-86-0)
- Statistics:
- All calculations conducted on the DPM values were performed with "R" (language and environment for statistical computing and graphics).
The mean values and standard deviations were calculated for the body weights.
Results and discussion
- Positive control results:
- The positive control substance (hexyl cinnamic aldehyde) was tested in a separate experiment in April 2016 (Envigo study number 1764300) at 5, 10 and 25% in AOO (acetone:olive oil (4+1 v/v)). It induced a positive reaction at a concentration of 25%, determined by a DPM/lymph node of 8170.5 compared with 1042.8 DPM/lymph node in the vehicle control group, leading to a SI of 7.84.
The EC3 value was calculated to be 10.6% (w/v) (using the results of 10 and 25% hexyl cinnamic aldehyde).
The historical control data of the last 10 positive control experiments revealed SI Values between 3.7 and 17.6 for 25% in AOO.
In vivo (LLNA)
Resultsopen allclose all
- Key result
- Parameter:
- SI
- Value:
- 1.16
- Test group / Remarks:
- 10% test group
- Key result
- Parameter:
- SI
- Value:
- 1.47
- Test group / Remarks:
- 25% test group
- Key result
- Parameter:
- SI
- Value:
- 1.02
- Test group / Remarks:
- 50% test group
- Key result
- Parameter:
- SI
- Value:
- 1
- Test group / Remarks:
- solvent control group (DMF)
- Cellular proliferation data / Observations:
- CELLULAR PROLIFERATION DATA:
No significant lymphoproliferation (SI ≥ 3) was observed for the test substance at treatment concentrations of 10, 25 and 50% (w/v). (For details refer to Table 5)
DETAILS ON STIMULATION INDEX CALCULATION: SI = DPM/lymph node of a treated group divided by the DPM/lymph node of the respective negative/solvent control group. Before DPM/lymph node values were determined, mean scintillation-background DPM (in main test = 18.5) was subtracted from test and control raw data. Since the lymph nodes of the animals of a dose group were pooled, DPM/ lymph node was determined by dividing the measured value by the number of pooled lymph nodes (= 8).
Following values (DPM/ lymph node) were obtained: 754.3, 873.6, 1110.9 and 769.4 for the vehicle control of the test substance (DMF) and 10, 25 and 50% test groups, respectively. (For details refer to Table 5)
EC3 CALCULATION: Based on the obtained results no EC3 value of the test substance could be calculated.
CLINICAL OBSERVATIONS:
No mortality or symptoms of systemic toxicity were observed in any treatment group. No signs of local skin irritation (indicated by an erythema score ≥ 3) or any other local skin effect were observed in any treatment group.
BODY WEIGHTS:
Body weights changes were within the range expected for animals of this strain and age.(For details refer to Table 6)
Any other information on results incl. tables
Results of the Pre-screen test
Table 1: Body Weights
Animal No. |
Concentration % |
Body Weight (g) |
|||
Prior to 1st application |
Prior to Sacrifice (Day 6) |
Difference |
Difference % |
||
1 |
25 |
20.6 |
22 |
1.4 |
6.8 |
2 |
50 |
23.7 |
22.6 |
-1.1 |
-4.6 |
Table 2: Ear Thickness
Animal No. |
Concentration % |
Ear Thickness |
||||||
Prior to 1st Application (μm) |
Prior to 3rd Application (μm) |
Prior to Necropsy (μm) |
Difference |
Ear Swelling |
Difference |
Ear Swelling Day 6 (%) |
||
Mean (Right and Left Ear) |
||||||||
1 |
25 |
237.5 |
245.0 |
242.5 |
7.5 |
3.2 |
5 |
2.1 |
2 |
50 |
235.0 |
252.5 |
247.5 |
17.5 |
7.4 |
12.5 |
5.3 |
Table 3: Ear Weights
Animal No. |
Concentration % |
Ear Weights after Necropsy (mg per animal) |
% Increase Compared to Vehicle Values |
1 |
25 |
27.83 |
8.3 |
2 |
50 |
29.29 |
14 |
Mean of historical controls (DMF): 25.7 mg/animal
Table 4: Ear Erythema
Animal No. |
Score |
|||||||
within 1 h after 1. Appl. |
24 h |
within 1 h after 2. Appl. |
24 h |
within 1 h after 3. Appl. |
24 h |
Day 5 |
Day 6 |
|
1 |
0* |
0 |
0* |
0* |
0* |
0 |
0 |
0 |
2 |
0* |
0 |
0* |
1* |
1* |
1* |
1* |
0 |
Score:
0 = No visible erythema
1 = Very slight erythema
2 = Well defined erythema
3 = Moderate to severe erythema
4 = Severe erythema to formation of eschar which prevents grading of erythema
*substance residue
Table 5: Stimulation index in mice (main test)
Compound |
Concentration [%] |
DPM/ lymph node |
Stimulation index |
Judgement |
DMF |
100 |
754.3 |
1.00 |
- |
Test item |
10 |
873.6 |
1.16 |
Negative |
25 |
1110.9 |
1.47 |
||
50 |
769.4 |
1.02 |
||
AOO* |
100 |
1042.8 |
1.00 |
- |
HCA* |
10 |
2908.9 |
2.79 |
Negative |
25 |
8170.5 |
7.84 |
Positive |
AOO = Acetone : olive oil (4:1 (v/v) mixture)
DMF = N,N -dimethylformamide
HCA = Hexyl cinnamic aldehyde
- = Not applicable
* = Performed in separate experiment
Table 6: Body weight (main test)
Compound |
Concentration [%] |
Animal ID No. |
Body weight |
|
Day 1 [g] |
Day 6 [g] |
|||
DMF |
100 |
1 |
20.8 |
21.0 |
2 |
20.5 |
21.8 |
||
3 |
20.2 |
20.9 |
||
4 |
20.8 |
21.3 |
||
Mean ± SD |
20.6 ± 0.3 |
21.3 ± 0.4 |
||
Test item |
10 |
5 |
19.8 |
20.2 |
6 |
21.1 |
21.7 |
||
7 |
21.0 |
21.0 |
||
8 |
19.8 |
21.7 |
||
Mean ± SD |
20.4 ± 0.7 |
21.0 ± 0.6 |
||
25 |
9 |
18.6 |
20.0 |
|
10 |
24.3 |
22.6 |
||
11 |
20.1 |
20.8 |
||
12 |
20.3 |
21.4 |
||
Mean ± SD |
20.8 ± 2.4 |
21.2 ± 1.1 |
||
50 |
13 |
22.5 |
22.5 |
|
14 |
19.9 |
20.9 |
||
15 |
19.7 |
20.1 |
||
16 |
18.1 |
19.1 |
||
Mean ± SD |
20.1 ± 1.8 |
20.7 ± 1.4 |
DMF = N,N -dimethylformamide
SD = Standard deviation
Applicant's summary and conclusion
- Interpretation of results:
- other: CLP/ EU GHS criteria not met, no classification required according to Regulation (EC) No 1272/2008
- Conclusions:
- CLP: not classified
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.